Pharma Business - December 9, 2025
Xinnate receives FDA IND approval
The US Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for TCP-25, a novel topical immunomodulatory peptide being developed for the treatment of Epidermolysis Bullosa (EB).
In a new job - December 9, 2025
PharmaRelations appoints new CDO and EVP Denmark
Niels Buch Leander has been appointed new Chief Digital Officer (CDO) and Executive Vice President (EVP) Denmark.
In a new job - December 9, 2025
He is the new Head of Project Development & Fundraising at MVA
Mathias Meijer joins Medicon Valley Alliance (MVA) with 14 years of experience developing major research, innovation and implementation projects across sectors.
New Market - December 9, 2025
Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing
Cinclus Pharma Holding's drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) for the treatment of gastroesophageal reflux disease (GERD).
In a new job - December 8, 2025
Zelluna appoints new Chief Financial Officer
Zelluna has announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026.
Clinical Trials - December 8, 2025
Aurealis Therapeutics announces positive Phase 2 results
The company has announced positive blinded evaluator efficacy results and completion of the Database Lock (DBL) in its DIAMEND Phase 2 clinical trial of AUP-16, the company’s lead asset for the treatment of non-healing neuro-ischemic Diabetic Foot Ulcers (DFUs).
